Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY-NC-ND 4.0EJHaem

Maternal and Fetal Outcomes of Pregnant Women With Sickle Cell Disease: A Single‐Center Canadian Study

  • Wing Man (Joanne) Lam1
  • Natalia Rydz1
  • Nancy Soliman2
  • Dawn Goodyear1
  • Kelsey Uminski1
  1. 1Division of Hematology and Hematologic Malignancies Department of Medicine University of Calgary Calgary Canada
  2. 2Division of Maternal‐Fetal Medicine Department of Obstetrics and Gynecology University of Calgary Calgary Canada
Read full textPDFDOICite

Abstract

Background: Sickle cell disease (SCD) increases the risk of complications during pregnancy. This study describes antenatal care patterns and maternal and fetal outcomes in pregnant women with SCD in a Canadian setting.

Methods: Women with SCD receiving antenatal/perinatal care through the Southern Alberta Rare Blood and Bleeding Disorders program (January 2010 to January 2025) were identified. Antenatal care, and maternal and fetal outcomes were assessed in periods before (2010–2019) and after (2020–2025) local multidisciplinary protocols for SCD pregnancy management were updated.

Results: 21 women (32 pregnancies; 31 neonates) were included. Most pregnancies were followed by maternal‐fetal medicine (81.3%), had regular fetal growth assessments (84.4%), and had high‐dose folic acid (90.6%) and acetylsalicylic acid (56.3%) supplementation; all were implemented more frequently following protocol update. Vaso‐occlusive crises occurred in 56.3% of pregnancies, infections requiring intravenous antibiotics occurred in 21.9%, preeclampsia occurred in 6.3%, and peripartum/postpartum hemorrhages occurred in 28.1%. Transfusions were required in 62.5% of pregnancies. There was one intensive care unit (ICU) admission and no maternal deaths. No neonates had fetal growth restriction and 16.1% required neonatal ICU admission. One stillbirth occurred at 23 weeks (mother had hyperhemolysis).

Conclusions: Multidisciplinary pregnancy management of women with SCD may improve antenatal care and maternal and fetal outcomes.

Related

  1. Maternal Delivery Outcomes Associated With Acute Sickle Cell Crisis: A National Inpatient Analysis
    John R Passman, Danielle Fastring
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Maternal cardiac and perinatal outcomes among pregnant individuals with tetralogy of Fallot
    Rahi Patel, Alyssa Singer, Bryon Gentile +2
    Obstetric MedicinePeer-reviewedLicence not statedFull textCardiovascular medicinePMC
  3. Early pregnancy overweight/obesity and adverse maternal outcomes among pregnant women in Eastern Ethiopia: an ambispective cohort study
    Assefa Tola, Tesfaye Gobena, Nega Assefa +2
    BMJ OpenPeer-reviewedLicence not statedGeneral medicineCrossref
  4. Predictors of family quality of life among Omani families of children with sickle cell disease: maternal stress and family structure in a cross-sectional study
    Wafa Al Jabri
    Child Health Nursing ResearchPeer-reviewedCC BY-NC-ND 4.0Full textHuman geneticsPMC
  5. Maternal and Fetal Outcomes in Pregnant Women with Burn Injuries: A Systematic Review and Meta-Analysis
    Juan Jose Parra Molina, Sergio Romero, Edgar Fabian Manrique Hernandez
    Journal of Burn Care & Research: Official Publication of the American Burn AssociationPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMC

Cite

BibTeXRIS
BibTeX
@article{lam2026maternal,
  title = {{Maternal and Fetal Outcomes of Pregnant Women With Sickle Cell Disease: A Single‐Center Canadian Study}},
  author = {Wing Man (Joanne) Lam and Natalia Rydz and Nancy Soliman and Dawn Goodyear and Kelsey Uminski},
  journal = {EJHaem},
  year = {2026},
  month = oct,
  doi = {10.1002/jha2.70445},
  url = {https://doi.org/10.1002/jha2.70445},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Maternal and Fetal Outcomes of Pregnant Women With Sickle Cell Disease: A Single‐Center Canadian Study
AU  - Wing Man (Joanne) Lam
AU  - Natalia Rydz
AU  - Nancy Soliman
AU  - Dawn Goodyear
AU  - Kelsey Uminski
PY  - 2026
DA  - 2026/10/26
JO  - EJHaem
DO  - 10.1002/jha2.70445
UR  - https://doi.org/10.1002/jha2.70445
AB  - Background: Sickle cell disease (SCD) increases the risk of complications during pregnancy. This study describes antenatal care patterns and maternal and fetal outcomes in pregnant women with SCD in a Canadian setting.  Methods: Women with SCD receiving antenatal/perinatal care through the Southern Alberta Rare Blood and Bleeding Disorders program (January 2010 to January 2025) were identified. Antenatal care, and maternal and fetal outcomes were assessed in periods before (2010–2019) and after (2020–2025) local multidisciplinary protocols for SCD pregnancy management were updated.  Results: 21 women (32 pregnancies; 31 neonates) were included. Most pregnancies were followed by maternal‐fetal medicine (81.3%), had regular fetal growth assessments (84.4%), and had high‐dose folic acid (90.6%) and acetylsalicylic acid (56.3%) supplementation; all were implemented more frequently following protocol update. Vaso‐occlusive crises occurred in 56.3% of pregnancies, infections requiring intravenous antibiotics occurred in 21.9%, preeclampsia occurred in 6.3%, and peripartum/postpartum hemorrhages occurred in 28.1%. Transfusions were required in 62.5% of pregnancies. There was one intensive care unit (ICU) admission and no maternal deaths. No neonates had fetal growth restriction and 16.1% required neonatal ICU admission. One stillbirth occurred at 23 weeks (mother had hyperhemolysis).  Conclusions: Multidisciplinary pregnancy management of women with SCD may improve antenatal care and maternal and fetal outcomes.
SN  - 2688-6146
ER  -